We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
114.00 | 1.01% | 11,382.00 | 11,380.00 | 11,384.00 | 11,412.00 | 11,288.00 | 11,288.00 | 746,021 | 14:08:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.64 | 176.5B |
By Maryam Cockar
AstraZeneca PLC (AZN.LN) on Wednesday said that the U.S. Food & Drug Administration has granted a priority review to its new drug application for tablets that treat breast cancer.
The FTSE 100-listed pharmaceutical company said that the regulator will review its application by the first quarter of 2018. Lynparza treats patients with germline breast cancer who have been previously treated with chemotherapy.
AstraZeneca said that the application is based on positive results from a phase 3 trial published in the New England Journal of Medicine. Lynparza was approved by the FDA in December 2014 in a capsule formulation.
Write to Maryam Cockar at maryam.cockar@dowjones.com
(END) Dow Jones Newswires
October 18, 2017 02:51 ET (06:51 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions